Oppenheimer analyst Jay Olson raised the firm’s price target on Viking Therapeutics to $46 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 results, with $29.3M OpEx and $362.1M cash, and provided a business update. Phase 2 VENTURE trial of VK2735 subQ formulation for obesity topline results are now expected in Q1 2024, supporting Oppenheimer’s optimism. Viking also expects oral Phase 1 topline results in Q1 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Viking Therapeutics (VKTX) Q4 Earnings Cheat Sheet
- Viking Therapeutics rumor highlighted by Betaville blog
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics management to meet with Oppenheimer